Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.
A user was frustrated with delays in getting finasteride for hair loss, was prescribed minoxidil, and found a vitamin B7 deficiency. They are questioning if the deficiency could cause receded temples and considering finding a new dermatologist.
The conversation discusses a personalized hair loss treatment plan based on DNA test results, recommending Minoxidil, Dutasteride, 17-alpha Estradiol, Cetirizine, and PRP sessions. The test identifies a high risk of hair loss due to DHT but a good response to Minoxidil, suggesting a tailored approach to treatment.
A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.
Reducing the dose of RU58841 from 25mg to 7.5mg topically helped minimize heart palpitations. Users discussed the cardiac effects of RU58841 and minoxidil, noting that no treatment is completely free of side effects.
Bryan Johnson uses a custom hair loss treatment that includes topical finasteride, minoxidil, azelaic acid, diclofenac, tea tree oil, rosemary oil, ginkgo biloba, biotin, and melatonin, which have shown varying degrees of effectiveness with minimal side effects. He also undergoes PRP and laser therapy, and has tried dutasteride mesotherapy.
User reports 12-week progress with HIMS spray, Minoxidil, micro-needling, and biotin. Notable baby hairs on crown and temples, hoping for further improvement.
RU58841 mixed with Minoxidil seems less effective over time, so the user plans to switch to a PG and Ethanol dilution for better results. They also consider using rosemary oil with Minoxidil to enhance RU58841 absorption.
A 28-year-old male using Tugain 10 minoxidil, Finpecia 1mg finasteride, Cipla Ketoconazole shampoo, and dermarolling 0.5mm weekly for 3-4 months is seeing some hair regrowth. Encouragement is given to continue the regimen.
Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.
RU58841 is discussed for hair loss treatment, with mixed reviews on its effectiveness and side effects. Users mention using it in an ethanol/PG solution and combining it with other treatments like dutasteride.
The conversation is about the effectiveness of using less than 20mg of RU58841, specifically 12.5mg, for hair loss treatment. People are discussing their experiences with different dosages of RU58841.
A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.
Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.
The conversation is about the lack of updates on GT20029, a potential hair loss treatment, and the user considering using dutasteride or RU58841 instead of minoxidil/finasteride due to the long duration of the latter treatments.
The conversation discusses hair loss treatments, specifically seeking a trusted supplier for RU58841. Minoxidil and finasteride are also mentioned as treatments.
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
The user experienced side effects with both oral and topical finasteride and is considering making their own hair loss treatment using CB-03-01 (Breezula) mixed with minoxidil due to fewer reported side effects. They plan to use a lower concentration than what was used in trials.
Hair loss treatments discussed include cosmeRNA, minoxidil, finasteride, RU58841, and pyrilutamide. Users debate effectiveness, side effects, and upcoming treatments, with some expressing skepticism and others optimism.
User 74775446 shares successful hair regrowth results using dermaroller/pen and minoxidil. Others discuss their experiences and concerns about finasteride side effects.
A user shared their 5-month progress in treating hair loss using HIMs topical finasteride and minoxidil, micro-needling with a 1.5mm needle, and RU-58841. The post includes progress pictures showing improvement from a NW7 hair loss stage.
A 17-year-old is concerned about potential hair loss due to maternal genetics and wonders if treatments like Minoxidil, Finasteride, or RU58841 will be effective. They hope their paternal genetics will help prevent hair loss or make treatments more effective.
The conversation discusses the effectiveness of RU58841 for hair loss compared to pyrilutamide, which failed to show significant hair regrowth in trials. Some users report personal side effects with RU58841 and question the criteria for success in hair loss treatments.
Alfatradiol is discussed as a weak 5ARI and estrogen, not as effective as minoxidil, RU58841, or CB-03-01, but a safe alternative for those who can't use finasteride. Users express frustration over the lack of strong FDA-approved topical antiandrogens for hair loss.
The conversation discusses experiences with hair loss treatments containing RootBioTec and Anagain. Users share their results and compare these treatments to Minoxidil, finasteride, and RU58841.
The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.